Difference between revisions of "Liu Tianshi"
From Bioblast
m (Gnaiger C moved page Tianshi Liu to Liu Tianshi) |
|||
Line 1: | Line 1: | ||
{{Person | {{Person | ||
|lastname= | |lastname=Liu | ||
|firstname= | |firstname=Tianshi | ||
|title=PhD | |title=PhD | ||
|institution=:::::[[File:Tianshi Liu.jpeg|right|150px|Tianshi Liu]] ย | |institution=:::::[[File:Tianshi Liu.jpeg|right|150px|Tianshi Liu]] ย |
Revision as of 17:16, 7 June 2023
Name | Liu Tianshi, PhD |
---|---|
Institution |
Lund University, Mitochondrial Medicine, SE |
Address | BMC A13, Sรถlvegatan 17, SE-221 84 |
City | Lund |
State/Province | |
Country | Sweden |
[email protected] | |
Weblink | |
O2k-Network Lab |
Labels:
Publications
Published | Reference | |
---|---|---|
Shao 2019 Cardiovasc Diabetol | 2019 | Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, Zhao J, Zhao Y, Li G, Liu T (2019) Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induce diabetic rats. Cardiovasc Diabetol 18:165. |
Zhang 2018 Cardiovasc Diabetol | 2018 | Zhang X, Zhang Z, Yang Y, Suo Y, Liu R, Qiu J, Zhao Y, Jiang N, Liu C, Tse G, Li G, Liu T (2018) Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits. Cardiovasc Diabetol 17:160. |
Zhang 2017 J Am Heart Assoc | 2017 | Zhang X, Zhang Z, Zhao Y, Jiang N, Qiu J, Yang Y, Li J, Liang X, Wang X, Tse G, Li G, Liu T (2017) Alogliptin, a dipeptidyl peptidase-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits. J Am Heart Assoc 6:e005945. |